European regulators flagged NAION, a sudden optic nerve injury, as a very rare possible side effect of semaglutide more than 15 months ago. Medscape looks at where that stands.
Recap by typeshit. Post by @medscape on Instagram.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
Dr Nadolsky, who treats obesity, responds to what wellness influencer Gary Brecka has said about GLP-1 medications.
South Korea's first homegrown obesity drug won approval, and Hanmi set its price to take on Wegovy and Mounjaro in the local market.
Loading…